Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
The objective was to evaluate the safety and effectiveness of soft-tissue augmentation
of calcium hydroxylapatite (Radiesse) in patients with facial lipoatrophy secondary
to human immunodeficiency virus disease.